439 related articles for article (PubMed ID: 23543483)
1. Parkinsonian apathy responds to dopaminergic stimulation of D2/D3 receptors with piribedil.
Thobois S; Lhommée E; Klinger H; Ardouin C; Schmitt E; Bichon A; Kistner A; Castrioto A; Xie J; Fraix V; Pelissier P; Chabardes S; Mertens P; Quesada JL; Bosson JL; Pollak P; Broussolle E; Krack P
Brain; 2013 May; 136(Pt 5):1568-77. PubMed ID: 23543483
[TBL] [Abstract][Full Text] [Related]
2. Non-motor dopamine withdrawal syndrome after surgery for Parkinson's disease: predictors and underlying mesolimbic denervation.
Thobois S; Ardouin C; Lhommée E; Klinger H; Lagrange C; Xie J; Fraix V; Coelho Braga MC; Hassani R; Kistner A; Juphard A; Seigneuret E; Chabardes S; Mertens P; Polo G; Reilhac A; Costes N; LeBars D; Savasta M; Tremblay L; Quesada JL; Bosson JL; Benabid AL; Broussolle E; Pollak P; Krack P
Brain; 2010 Apr; 133(Pt 4):1111-27. PubMed ID: 20237128
[TBL] [Abstract][Full Text] [Related]
3. [The effectiveness and tolerance of piribedil as adjunct therapy to levodopa in patients with Parkinson's disease: a nine month follow up].
Salazar Tortolero G; Wix Ramos R; Salazar Aladrén P; Jiménez León JC
Rev Neurol; 2004 Apr 16-30; 38(8):715-9. PubMed ID: 15122540
[TBL] [Abstract][Full Text] [Related]
4. Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study.
Rascol O; Dubois B; Caldas AC; Senn S; Del Signore S; Lees A;
Mov Disord; 2006 Dec; 21(12):2110-5. PubMed ID: 17013922
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study.
Ziegler M; Castro-Caldas A; Del Signore S; Rascol O
Mov Disord; 2003 Apr; 18(4):418-25. PubMed ID: 12671949
[TBL] [Abstract][Full Text] [Related]
6. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
[TBL] [Abstract][Full Text] [Related]
7. A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease.
Brooks DJ; Abbott RJ; Lees AJ; Martignoni E; Philcox DV; Rascol O; Roos RA; Sagar HJ
Clin Neuropharmacol; 1998; 21(2):101-7. PubMed ID: 9579296
[TBL] [Abstract][Full Text] [Related]
8. Antidepressant-like properties of the anti-Parkinson agent, piribedil, in rodents: mediation by dopamine D2 receptors.
Brocco M; Dekeyne A; Papp M; Millan MJ
Behav Pharmacol; 2006 Nov; 17(7):559-72. PubMed ID: 17021388
[TBL] [Abstract][Full Text] [Related]
9. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
Barone P; Poewe W; Albrecht S; Debieuvre C; Massey D; Rascol O; Tolosa E; Weintraub D
Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson's disease: a 6-month open study.
Suwantamee J; Nidhinandana S; Srisuwananukorn S; Laptikultham S; Pisarnpong A; Chankrachang S; Bundhukul A
J Med Assoc Thai; 2004 Nov; 87(11):1293-300. PubMed ID: 15825702
[TBL] [Abstract][Full Text] [Related]
11. From the cell to the clinic: a comparative review of the partial D₂/D₃receptor agonist and α2-adrenoceptor antagonist, piribedil, in the treatment of Parkinson's disease.
Millan MJ
Pharmacol Ther; 2010 Nov; 128(2):229-73. PubMed ID: 20600305
[TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind study of a skin patch of a dopaminergic agonist, piribedil, in Parkinson's disease.
Montastruc JL; Ziegler M; Rascol O; Malbezin M
Mov Disord; 1999 Mar; 14(2):336-41. PubMed ID: 10091630
[TBL] [Abstract][Full Text] [Related]
13. End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: a pharmacokinetic/pharmacodynamic, randomized, double-blind study.
Simon N; Micallef J; Reynier JC; Lesourd M; Witjas T; Alicherif A; Azulay JP; Blin O
Mov Disord; 2005 Jul; 20(7):803-9. PubMed ID: 15726579
[TBL] [Abstract][Full Text] [Related]
14. Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease.
Perez-Lloret S; Rascol O
CNS Drugs; 2016 Aug; 30(8):703-17. PubMed ID: 27344665
[TBL] [Abstract][Full Text] [Related]
15. Subthalamic stimulation in Parkinson's disease: restoring the balance of motivated behaviours.
Lhommée E; Klinger H; Thobois S; Schmitt E; Ardouin C; Bichon A; Kistner A; Fraix V; Xie J; Aya Kombo M; Chabardès S; Seigneuret E; Benabid AL; Mertens P; Polo G; Carnicella S; Quesada JL; Bosson JL; Broussolle E; Pollak P; Krack P
Brain; 2012 May; 135(Pt 5):1463-77. PubMed ID: 22508959
[TBL] [Abstract][Full Text] [Related]
16. [The agonist of dopamine receptors piribedil in treatment of Parkinson's disease].
Pilipovich AA; Golubev VL
Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(6):83-90. PubMed ID: 28745677
[TBL] [Abstract][Full Text] [Related]
17. What can rodent models tell us about apathy and associated neuropsychiatric symptoms in Parkinson's disease?
Magnard R; Vachez Y; Carcenac C; Krack P; David O; Savasta M; Boulet S; Carnicella S
Transl Psychiatry; 2016 Mar; 6(3):e753. PubMed ID: 26954980
[TBL] [Abstract][Full Text] [Related]
18. Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial.
Lhommée E; Wojtecki L; Czernecki V; Witt K; Maier F; Tonder L; Timmermann L; Hälbig TD; Pineau F; Durif F; Witjas T; Pinsker M; Mehdorn M; Sixel-Döring F; Kupsch A; Krüger R; Elben S; Chabardès S; Thobois S; Brefel-Courbon C; Ory-Magne F; Regis JM; Maltête D; Sauvaget A; Rau J; Schnitzler A; Schüpbach M; Schade-Brittinger C; Deuschl G; Houeto JL; Krack P;
Lancet Neurol; 2018 Mar; 17(3):223-231. PubMed ID: 29452685
[TBL] [Abstract][Full Text] [Related]
19. [Action of piribedil in Parkinson disease. Multicenter study].
Ziégler M; Rondot P
Presse Med; 1999 Sep; 28(26):1414-8. PubMed ID: 10518963
[TBL] [Abstract][Full Text] [Related]
20. Switching from levodopa to the long-acting dopamine D2/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates.
Smith LA; Jackson MJ; Johnston L; Kuoppamaki M; Rose S; Al-Barghouthy G; Del Signore S; Jenner P
Clin Neuropharmacol; 2006; 29(3):112-25. PubMed ID: 16772809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
